Enozertinib in EGFR Exon 20ins mutants: a game changer for CNS metastases, or a temporary conquest? Authors: Naoki Furuya Published: 2026 We would like to comment on enozertinib, a highly selective brain-penetrant EGFR inhibitor for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (Ex20ins) and atypical mutations by Junttila MR et al., which was published in Cancer Research (1). The objective of this study was to evaluate enozertinib for EGFR Ex20ins and atypical mutations in vitro and in vivo preclinical models. Amivantamab in combination with carboplatin plus pemetrexed was established in the PAPILLON study for patients with EGFR Ex20ins as the first-line setting (2), and is strongly recommended in current guidelines (3). However, the PAPILLON regimen requires intravenous administration and involves complex management of adverse events (AEs). Meanwhile, mobocertinib, which previously received accelerated approval by U.S. Food and Drug Administration (FDA), was withdrawn from the market after failing to demonstrate clinical benefits in the EXCLAIM-2 phase III trial (4). This failure highlighted its limited efficacy for brain metastases; specifically, the central nervous system (CNS) was the initial site of disease progression in 38% of overall progressive cases and in 68% of patients with baseline brain metastases. Considering that nearly 50% of EGFR-mutant cases eventually develop brain metastases during the disease course in general, the development of an ideal oral epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) remains an unmet medical need. Furthermore, one that simultaneously achieves potent EGFR Ex20ins activity and superior brain penetrance without compromising selectivity over wild-type EGFR would be desirable. First, the authors screened around 1,300 compounds from their noncovalent kinase library. They identified Compound 3 which is a highly selective EGFR inhibitor. Furthermore, the authors demonstrated that sequential structural modifications, specifically the incorporation of a cyclopropylpiperazine-containing amine moiety, successfully enhanced blood-brain barrier (BBB) permeability. As a culmination of several steps, they finally discovered enozertinib. In vitro proliferation inhibition assays using Ba/F3 cells, enozertinib demonstrated potent inhibitory activity to multiple Ex20ins mutation subtypes at low nanomolar. Notably, this inhibitory potency is approximately 10-fold greater than that of osimertinib. Furthermore, in vivo evaluations demonstrated that enozertinib elicits robust tumor regression. This potent efficacy extends beyond Ex20ins to encompass PACC (P-loop and αC-helix-compressing) mutations—including G719X and S768I—along with other rare, uncommon EGFR mutation variants. The authors demonstrated brain penetrance assessment and pharmacokinetics (PK) studies using animal models. Notably, unbound brain/plasma drug concentration was almost the same as osimertinib and higher than mobocertinib and zipalertinib. Furthermore, enozertinib demonstrated promising antitumor activity in a brain metastasis in vivo mice model by directly transplanting PC9-Luc cells into mouse brains. As a highlight of this study, a highly representative case report from an ongoing phase I clinical trial (NCT05315700) was presented. Following oral administration of enozertinib, a sustained complete response (CR) was confirmed not only in systemic extracranial lesions but also across all brain metastases. The greatest hurdle during the drug discovery stage is achieving BBB permeability. Having determined the structure of enozertinib, elucidated its binding mode via crystallography, and validated its potency against Ex20ins in in vitro assays, the authors successfully demonstrated its CNS efficacy in a mouse model of brain metastasis and provided clinical proof of concept by presenting a representative case from the phase I trial (ClinicalTrials.gov: NCT05315700). However, this study is subject to several limitations. First, EGFR Ex20ins mutations are highly heterogeneous, encompassing over 100 molecular subtypes (5). In this study, the authors evaluated cell viability across only five Ex20ins subtypes; thus, the therapeutic efficacy of enozertinib against other rare variants remains uncharacterized, and antitumor activity may vary depending on the specific subtype. Second, in the brain metastasis mouse model, the authors established the intracranial tumors by directly transplanting PC9 cells, which are an EGFR exon 19 deletion (Ex19del) cell line. Consequently, the antitumor efficacy and aggressiveness of CNS metastases could differ between Ex20ins and Ex19del variants. While the representative case demonstrated an encouraging response, it remains a single case report showing only an initial therapeutic response. In this phase I study, enozertinib at 120 mg achieved a preliminary promising intracranial response rate of 71% (5/7) in treatment-naive patients with EGFR Ex20ins NSCLC (6). The final results regarding the objective response rate (ORR) and duration of response (DoR) for CNS metastases in the phase I/II study must be carefully awaited. Third, the underlying resistance mechanisms remain elusive. Enozertinib inhibits not only EGFR but also ERBB2 (HER2) and ERBB3. Simultaneous inhibition of the other ERBB family could potentially activate alternative bypass pathways, which may influence subsequent therapies and patient prognosis after the development of enozertinib resistance. Elucidating the mechanisms of acquired resistance will provide a rationale for optimal subsequent treatment strategies, such as combining TKIs with cytotoxic chemotherapy or antibody-drug conjugates (ADCs). In summary, the therapeutic landscape for EGFR Ex20ins mutations is evolving rapidly (7,8), representing a paradigm shift that was unachievable a decade ago. Clinical development is progressing, with several phase III trials of novel EGFR-TKIs currently ongoing (Table 1). The development of next-generation agents holds substantial potential to replicate the landmark progression‑free survival (PFS) milestones established in common EGFR-mutated NSCLC, such as Ex19del and L858R. Consequently, achieving long-term efficacy remains an achievable goal for the near future. Table 1Investigational drugs for EGFR Ex20 insertion mutations in the first-line settingVariableTKI monotherapyTKI + ChemoEnozertinibSunvozertinibFurmonertinibZipalertinib + platinum† + PEMStudyNCT05315700WU-KONG28 (NCT05668988)FURVENT (NCT05607550)REZILIENT3 (NCT05973773)PhasePhase I/IIPhase IIIPhase IIIPhase IIIControl armSingle armCb + PEMPlatinum† + PEMPlatinum† + PEMSample size (N)350320375272Primary endpointMTD/RP2D/ORRPFS (BICR)PFS (BICR)PFS (BICR)Crossover Tx×○○○StatusOn goingOn goingOn goingOn goingEstimated study completionSep/2027Oct/2027Feb/2028Aug/2026/8†, carboplatin or cisplatin based on investigator’s choice. ×, no; ○, yes. BICR, blinded independent central review; Cb, carboplatin; Chemo, chemotherapy; MTD, maximum tolerated dose; ORR, objective response rate; PEM, pemetrexed; PFS, progression-free survival; RP2D, recommended phase 2 dose; TKI, tyrosine kinase inhibitor; Tx, treatment. Investigational drugs for EGFR Ex20 insertion mutations in the first-line setting †, carboplatin or cisplatin based on investigator’s choice. ×, no; ○, yes. BICR, blinded independent central review; Cb, carboplatin; Chemo, chemotherapy; MTD, maximum tolerated dose; ORR, objective response rate; PEM, pemetrexed; PFS, progression-free survival; RP2D, recommended phase 2 dose; TKI, tyrosine kinase inhibitor; Tx, treatment. Supplementary The article’s supplementary files as Acknowledgments The author wishes to thank Mr. Jason Tonge from St. Marianna University School of Medicine for reviewing the language of this article. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the editorial office, Translational Lung Cancer Research. The article has undergone external peer review. Funding: None. Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0817/coif). N.F. reports personal fees and honoraria for lectures from AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, MSD, Johnson & Johnson, and Regeneron, outside the submitted work. The author has no other conflicts of interest to declare. References Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0817/prf Supplementary Materials The article’s supplementary files as